Clinical Trial Details
— Status: Completed
Administrative data
| NCT number |
NCT04208477 |
| Other study ID # |
UMCLjubljana Stellate |
| Secondary ID |
|
| Status |
Completed |
| Phase |
N/A
|
| First received |
|
| Last updated |
|
| Start date |
November 1, 2021 |
| Est. completion date |
December 31, 2023 |
Study information
| Verified date |
December 2023 |
| Source |
University Medical Centre Ljubljana |
| Contact |
n/a |
| Is FDA regulated |
No |
| Health authority |
|
| Study type |
Interventional
|
Clinical Trial Summary
Blood flow through the brain is reduced after brain damage. Secondary brain ischemia caused
by hypoxia and hypotension, further increase the susceptibility of the ischemically
compromised brain to secondary impairment during this period. In order to determine whether
and to what extent blockage of the stellate ganglion (BSG) affects the blood flow to the
injured brain, the investigators will measure the variables of brain blood flow before and
after BSG using computed tomography angiography (CTA), trans-cranial Doppler ultrasound
(TCD), intracranial pressure (ICP) and perfusion computed tomography (PCT) of the brain. At
the same time, the investigators would like to evaluate whether and to what extent BSG
affects the aseptic inflammatory brain injury response and the biochemical indicators of
brain damage in patients with moderate and severe brain injury.
Description:
Hypothesis
Stellate ganglion blockade in patients with moderate and severe brain damage:
1. Increases the diameter of the brain arteries and blood flow through the brain
2. Do not interfere with intracranial pressure
3. Reduces aseptic inflammatory reaction of the damaged brains measured by IL-6 and reduces
damage of the brain tissue measured by protein S100B (S100B), neuron specific enolase
(NSE) and glial fibrillary acidic protein (GFAP).
Study design and method description
The study will include 40 subjects of both sexes (18-70 years old) with moderate and severe
head injury who will be treated surgically and/or conservatively at the Intensive Care Center
(CIT) of the Department of Anesthesiology and Intensive Care UKC Ljubljana. The study will
include patients who underwent computed tomography angiography of the brain (CTA) and
received an intra-parenchymal intracranial pressure monitor electrode (ICP) at admission to
the UKC Ljubljana Emergency Center or during CIT treatment. After primary conservative or
surgical care, the subjects will be transferred for further treatment at CIT. Subjects will
be sedated and mechanically ventilated. To maintain target cerabral perfusion pressure (CPP),
the investigators will give an infusion of noradrenaline as needed. The study will not
include subjects with primary decompression craniectomy and radiological signs of progression
of intracranial hematomas, subjects in a barbiturate coma, and subjects with a norepinephrine
dose greater than 0.2 mcg/kg/min. The study will not include pregnant women, children,
patients with known hypersensitivity to iodine contrast media and local anesthetics, and
patients with poor renal function (estimated glomerular filtration below 30ml / min /
1.73m2).
The research will be conducted during patient treatment at CIT. The investigators will begin
the investigation after positive positive opinions from the Medical Ethics Commission of the
Republic of Slovenia, and obtained written consent form patient's family members or official
legal representatives.
The effect of BSG on brain blood flow and the diameter of brain vessels will be evaluated by
CTA, PCT, TCD.
BSG will be done during the first week after admission at CIT on the same patient's side of
the ICP position. One hour after BSG, control CTA in PCT will be done. TCD od the left and
right middle brain artery (ACM) will be performed one hour before and after BSG.
TCD will be used to measure the rate of blood flow through ACM in systole-Vs in diastole-Vd
and pulsatility index (PI). The investigators will compare Vs, Vd values and PI before and
after BSG.
Possible changes in the diameter of large brain vessels after BSG will be compared between
CTA done at the emergency center or during CIT treatment and a control CTA after BSG. For
standard diameter measurement sites, the investigators will take the middle third of M1 and
the proximal part of the M2 segment of the ACM, the middle third of the A1 and A2 segments of
the anterior brain artery (ACA), the P1 segment and the first part of P2 segment of the
posterior brain artery (ACP), the terminal part of the interior carotid artery (ACI), the
middle third of the intradural part of the vertebral artery and middle third of the basilar
artery. Changes in the diameter of the brain vessels will be presented numerically and
descriptively.
With PCT-produced color maps beside qualitative evaluation od the possible changes of the
brain blood flow on the left and right brain hemisphere after BSG, the investigators will
also evaluate changes in regional brain blood volume (rCBV), regional brain blood flow
(rCBF), mean transition time (MTT). Outside the contusion regions, the investigators will
mark the region of interest (ROI) of 500 mm2 for ACA, ACM and ACP perfusion areas. Siemens
SyngoVia software will be used.
PCT and CTA will be done by the helical CT tomogram (Somatom, Siemens, Erlangen, Germany). A
40 ml non-ionic low-osmolar iodine contrast medium, 370 mg/ml iopromide (Ultravist; Bayer
HealthCare, Berlin, Germany) will be used. It will be injected at a flow rate of 5 ml/s into
a cubital vein. Perfusion imaging will be initiated 7 seconds after the injection of
contrast.
Blood samples for the determination of IL6, NSE, S100B in GFAP will be drawn from the right
external jugular vein and peripheral artery (radial or femoral artery) one hour before and 1,
6, 12, 24 hours after BSG. The investigators will compare IL6, NSE, S100B, GFAP values in
venous blood from right jugular vein before v after BSG. A comparation of the values of IL6,
NSE, S100B, GFAP in venous blood from the right internal jugular vein in arterial blood taken
from the peripheral artery will be done as well. Blood samples will be sent for analysis to
the central laboratory of UKC Ljubljana.
Brain oxygenation will be measured with a non-invasive method on both fronts using Near
Infrared Spectroscopy (NIRS). NIRS measurement values will be measured immediately before BSG
and within 5, 10, 15, 20, 25 and 30 minutes after BSG.
BSG will be done ipsilaterally to the inserted ICP electrode. BSG will be done under
ultrasound control at the C6-C7 level, with a lateral approach with a Stimulplex Ultra 360
5cm needle (B.Brown). A 6-15 MHz high frequency probe will be used. BSG will be done always
by the same anesthesiologist. The injection site and the ultrasound probe will be aseptically
prepared. The ultrasound probe will be placed transversely to the neck axis at the height of
the sixth cervical vertebra. After preliminary verification of the needle tip position over
the long cervical muscle and under the prevertebral fascia and after negative aspiration, 8
ml of 0.5% levobupivacaine will be injected. Because het investigator's subjects will be
sedated, onset of the BSG will be confirmed 10 minutes after the blockade, by the onset of
three signs of Horner's syndrome (ptosis, myosis, enophthalmus, anhydrosis, conjunctival
hyperemia): enophthalmus, anhydrosis, conjunctival hyperemia.
ICP in CPP will be continuously measured before and after BSG. The data will be analyzed in
graphical display using IBM SPSS Statistics statistical programs, ver. 25 and Microsoft
Excel. The variables will be presented as mean values with standard deviation or as median
with interquartile range. Using the paired t-test, the investigators will compare the average
values of the sample's numerically variables. Significant differences will be defined as
p<0,05.
Expected results
When investigating the effect of BSG on the brain circulation and inflammatory response in
subjects with moderate and severe brain damage, the investigators expect a significant
increase in the diameter of the large brain arteries, and thus a positive effect of BSG on
the brain circulation of the injured brain (decreased mean blood transition time, increased
blood volume in the brain, and increased blood flow through the brain). The investigators
estimate that BSG will not change the intracranial pressure. The investigators expect NIRS
values to be significantly higher after the blockade than before the blockade. Due to the
positive effects of BSG on the aseptic inflammatory response of non-injured brain, BSG is
expected to have the same effect in the injured brain. The investigators also expect BSG will
decrease the concentration of biochemical indicators of inflammation and damage to neurons
and glia.
